Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djae196 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Sydnie Stackland und 4 weiteren Autor:innen. Beteiligte Einrichtung: Panalgo, Boston, MA, USA. Hauptthemen laut MEDLINE: Neoplasms, United States Food and Drug Administration, Genomics, Centers for Medicare and Medicaid Services, U.S.. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCCN Foundation, Rising Tide Foundation, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Although use of comprehensive genomic profiling was approved by a novel Centers for Medicare & Medicaid Services–US Food and Drug Administration parallel review process, the quality of the supporting evidence is unclear. We evaluated the rigor of the peer-reviewed literature cited in the National Coverage Determination Memorandum for the FoundationOneCDx (Foundation Medicine, Inc, Cambridge, MA).
Methods
We identified studies cited in the memorandum. Two independent researchers evaluated each study and applied a modified version of the Fryback and Thornbury hierarchy, an established framework for evaluating the efficacy of diagnostic tests. Studies focused on clinical outcomes were then categorized by study design, guided by recommendations from the Center for Medical Technology Policy.
Results
The sample included 113 scientific studies. The majority (60/113 [53.1%]) used comprehensive genomic profiling outside the course of clinical care, and there was substantive heterogeneity in the cancer types assessed and the sequencing depth. We found 8 (7.1%) studies that assessed whether clinical care had changed due to comprehensive genomic profiling testing, and 38 (33.6%) assessed clinical outcomes. After excluding studies that tested for 5 or fewer genomic alterations, 25 remained in the clinical outcomes sample: Of these, only 1 included a comparator group that did not receive comprehensive genomic profiling testing. Only 4 studies used FoundationOneCDx as the primary genomic test, none of which compared the outcomes of patients who did vs did not receive the test.
Conclusions
The findings indicate gaps in the supporting evidence for broad comprehensive genomic profiling use in patients with solid tumors. More rigorous studies that assess clinical utility would better inform the approval process for novel diagnostic tests.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Panalgo, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
- Cancer Outcomes Public Policy and Effectiveness Research Center, Yale School of Medicine, New Haven, CT, USA.
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
- Section of General Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
ORCID-Profile: Cary P Gross
Förderung
- NCCN Foundation
- Rising Tide Foundation
- NCATS NIH HHS
- AstraZeneca
- Bristol Myers Squib Foundation
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Stackland, S., Schnabel, D., Dinan, M. A., Presley, C. J., & Gross, C. P. (2025). Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae196
Vancouver
Stackland S, Schnabel D, Dinan MA, Presley CJ, Gross CP. Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae196
BibTeX
@article{Stackland2025,
author = {Stackland, Sydnie and Schnabel, Dominic and Dinan, Michaela A and Presley, Carolyn J and Gross, Cary P},
title = {Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djae196}
}
EUVIMED